Skip to content

A Real-world Study of DEXTENZA® for the Treatment of Ocular Inflammation and Pain after Cataract Surgery

A Real-world Study to Evaluate the Safety and Efficacy of DEXTENZA® for the Treatment of Ocular Inflammation and Pain after Cataract Surger

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079737
Enrollment
Unknown
Registered
2024-01-10
Start date
2022-01-13
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular inflammation and pain following ophthalmic surgery

Interventions

Test group:Dexamethasone Ophthalmic Insert

Sponsors

Boao Super Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged = 18 years old at screening; 2) With a cataract and is expected to undergo phacoemulsification cataract surgery with clear corneal incision and implantation of a posterior chamber intraocular lens;

Exclusion criteria

Exclusion criteria: 1) Currently have suspected or known malignancy or currently receiving anti-tumor therapies; 2) Pregnant or lactating women; women who plan to become pregnant during the study; or women of child-bearing potential (i.e., non-menopausal or not surgically sterilized women) who will not use adequate contraception methods; 3) Subjects with glaucoma or receiving anti-glaucoma medication; 4) With active or history of chronic or recurrent inflammatory eye diseases (e.g., iritis, scleritis, uveitis, iridocyclitis, rubeosis iritis) in the study eye; 5) With evidence of acute external ocular infections (bacterial, viral and/or fungal infections such as smallpox, varicella, and other viral diseases of the cornea and conjunctiva); tuberculosis of the eye; corneal dystrophies; active corneal ulcers, intraocular infections, dysthyroid ophthalmopathy, active chalazion, or uncontrolled blepharitis in the study eye; 6) Subjects with unexplained diseases (e.g., systemic or other ocular disorders or abnormalities) whose enrollment may compromise the subject’s health or the validity of the study results are ineligible, as determined by the investigator.

Design outcomes

Primary

MeasureTime frame
Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14;

Secondary

MeasureTime frame
Absence of pain (i.e., score of '0') in the study eye at Day 8;Absence of cells in the anterior chamber of the study eye at Days 2, 8 and 30;Absence of pain in the study eye at Days 2,14, and 30;

Countries

China

Contacts

Public ContactWei Chen

Boao Super Hospital

chenweimd@hotmai.com+86 137 5772 8118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026